{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BridgeBio Pharma, Inc."},"Symbol":{"label":"Symbol","value":"BBIO"},"Address":{"label":"Address","value":"421 KIPLING STREET SUITE 250, PALO ALTO, California, 94301, United States"},"Phone":{"label":"Phone","value":"+1 650 391-9740"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology."},"CompanyUrl":{"label":"Company Url","value":"https://www.bridgebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jonathan C. Fox","title":"Chief Medical Officer"},{"name":"Neil Kumar","title":"Chief Executive Officer & Director"},{"name":"Richard H. Scheller","title":"Chairman-Research & Development"},{"name":"Thomas Trimarchi","title":"President & Chief Operating Officer"},{"name":"Uma Sinha","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}